The landscape of the US Regenerative Medicine Market in 2026 is being profoundly influenced by the "Opportunity Zone 2.0" redesignations under the One Big Beautiful Bill Act (OBBBA). These new federal guidelines have transformed biotech real estate from a speculative asset into a strategic cornerstone for long-term clinical manufacturing. With the first round of original designations set...